Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.62 |
| ▸ | ROS1 | P08922 | 5/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.61 |
| ▸ | MAP3K9 | P80192 | 2/20 | 0.61 |
| ▸ | INSR | P06213 | 4/20 | 0.60 |
| ▸ | IGF1R | P08069 | 4/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | MET | P08581 | 3/20 | 0.59 |
| ▸ | PLK4 | O00444 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | PAK4 | O96013 | 2/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10208085 | 0.93 | LRRK2 (0.62) | LRRK2ALKROS1MKNK2MAP3K9 | |
| SCHEMBL12917681 | 0.91 | LRRK2 (0.55) | LRRK2ALKROS1MKNK2IGF1R | |
| SCHEMBL10207520 | 0.91 | ZAP70 (0.68) | LRRK2ALKMKNK2IGF1REGFR | |
| SCHEMBL10207529 | 0.89 | LRRK2 (0.65) | LRRK2ALKROS1MKNK2MAP3K9 | |
| SCHEMBL12780106 | 0.87 | ZAP70 (0.62) | LRRK2ALKROS1INSRIGF1R | |
| SCHEMBL26451583 | 0.87 | EGFR (0.77) | LRRK2ALKROS1MKNK2MAP3K9 | |
| SCHEMBL30123962 | 0.87 | EGFR (0.77) | LRRK2ALKROS1MKNK2MAP3K9 | |
| SCHEMBL14556271 | 0.85 | LRRK2 (0.86) | LRRK2MKNK2MAP3K9 | |
| SCHEMBL12781205 | 0.85 | ALK (0.56) | LRRK2ALKROS1INSRIGF1R | |
| SCHEMBL10208739 | 0.85 | ZAP70 (0.59) | LRRK2ALKROS1INSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660458-B1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-2287156-A1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | Novartis AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | LRRK2 3211/4885ALK 3384/4885ROS1 3425/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | LRRK2 3157/4885ALK 3200/4885ROS1 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.